February 12, 2020

Stephanie Byrum, Ph.D.

Assistant Professor
Department of Biochemistry and Molecular Biology
UAMS College of Medicine
Director of UAMS Bioinformatics Core

Research Interest Statement

Dr. Byrum’s research is two-fold: 1. Understanding the epigenetic mechanisms of triple negative breast cancer and 2. Developing bioinformatics tools for multi-omics data.

Breast cancer is the most common malignancy in women and the second most common cause of cancer-related death in women. Breast cancers are subdivided into types based on the expression of three receptors that respond to estrogen, progesterone and human epidermal growth factor. Targeted therapies are used clinically for treatment of cancers expressing one or more of these receptors. Breast cancers that lack expression of all three receptors are classified as triple-negative breast cancers (TNBC). Targeted therapies for TNBC do not currently exist, making these tumors the most difficult to treat. Dr. Byrum’s research focus involves a multi-omics approach to understand the epigenetic mechanisms of TNBC.

Dr. Byrum’s lab is also interested in developing bioinformatics tools that allow researchers to easily interpret large omics data in order to drive their research forward. The lab has developed three interactive shiny applications, ProteiNorm, ProteoViz, and PTMViz for proteomics analysis. These tools provide an interactive environment for the evaluation of normalization methods, quantitation of phosphopeptides and quantitation of histone post-translational modifications.

Dr. Byrum’s Cancer-related Grants

NIH/NCI: 1R01CA236209

Alan Tackett: Site Project PI

Stephanie Byrum: Co-I

Title “Identification of Druggable Targets to Complement Melanoma Therapy”

06/15/2019 to 05/31/2024



NIH/NCI: 5R01HD093461

Angus Macnicol: Site Project PI

Stephanie Byrum: Co-I

Title “Control of pituitary cell plasticity through regulated mRNA translation”

09/01/2018 to 06/30/2023


*annual cancer-related direct cost

Dr. Byrum’s UAMS Collaborators

Department of Biochemistry and Molecular Biology

Alicia Byrd, Ph.D.

Kevin Raney, Ph.D.

Samantha Kendrick, Ph.D.

Sam Mackintosh, Ph.D.

Alan Tackett, Ph.D.

Department of Internal Medicine

Rick Edmondson, Ph.D.

Department of Neurobiology and Developmental Sciences

Angus MacNicol, Ph.D.

Department of Microbiology and Immunology

Mark Smeltzer, Ph.D.

Department of Pharmacology and Toxicology

Eric Peterson, Ph.D.

Dr. Byrum’s External Collaborators

Sean Taverna, Ph.D., Johns Hopkins School of Medicine

Opportunities for Collaboration

I am always looking for opportunities to collaborate with colleagues at UAMS. I have an open-door policy for discussing new ideas, projects and collaborations. My scientific expertise is in bioinformatics and epigenetics, which can often drive new collaborations.

You May Not Know That …

I enjoy hiking the trails in Arkansas, fishing, biking along the river trail and kayaking. I really enjoy adventurous vacations, such as paragliding in Switzerland.

Recent Cancer-related Publications

Chiang TC, Koss B, Su LJ, Washam CL, Byrum SD, Storey A, Tackett AJ. (2019) Effect of Sulforaphane and 5-Aza-2′-Deoxycytidine on Melanoma Cell Growth. Medicines (Basel). Jun 27;6(3). pii: E71. doi: 10.3390/medicines6030071. PMID: 31252639

Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ. (2019) Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. Mar 15;79(6):1113-1123. doi: 10.1158/0008-5472.CAN-18-1722. Epub 2019 Jan 23. PMID: 30674537; PMCID: PMC6420873.

Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ. (2017) Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep. Apr 11;7(1):807. doi: 10.1038/s41598-017-01000-2. PMID: 28400597; PMCID: PMC5429745.

Byrum SD, Holthoff ER, Mackintosh SG, Kelly T, Tackett AJ, Quick CM, Post SR. (2017) Vulvar squamous cell carcinoma aggressiveness is associated with differential expression of collagen and STAT1. Clin Proteomics.  Dec 6;14:40. doi: 10.1186/s12014-017-9175-8. PMID: 29225558

Sengupta D, Byrum SD, Avaritt NL, Davis L, Shields B, Mahmoud F, Reynolds M, Orr LM, Mackintosh SG, Shalin SC, Tackett AJ. (2016) Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma. Mol Cell Proteomics. Mar;15(3):765-75. doi: 10.1074/mcp.M115.053363. PMID: 26621846; PMCID: PMC4813699.